Non-antibiotic antimicrobial triclosan induces multiple antibiotic resistance through genetic mutation

Image from: Sciencedirect.com

Mutations led to resistance by up-regulating beta-lactamase and multi-drug efflux pump.

Antibiotic resistance poses a major threat to public health. Overuse and misuse of antibiotics are generally recognized as the key factors contributing to antibiotic resistance. However, whether non-antibiotic, anti-microbial (NAAM) chemicals can directly induce antibiotic resistance is unclear. We aim to investigate whether the exposure to a NAAM chemical triclosan (TCS) has an impact on inducing antibiotic resistance on Escherichia coli. Here, we report that at a concentration of 0.2 mg/L TCS induces multi-drug resistance in wild-type Escherichia coli after 30-day TCS exposure.

The oxidative stress induced by TCS caused genetic mutations in genes such as fabI, frdD, marR, acrR and soxR, and subsequent up-regulation of the transcription of genes encoding beta-lactamases and multi-drug efflux pumps, together with down-regulation of genes related to membrane permeability. The findings advance our understanding of the potential role of NAAM chemicals in the dissemination of antibiotic resistance in microbes, and highlight the need for controlling biocide applications.

News source: www.sciencedirect.com
DOI: https://doi.org/10.1016/j.envint.2018.06.004

Targeting Phage & Antibiotic Resistance World Congress 2018 concluding remarks

The 5th World Congress on Targeting Infectious Diseases: Targeting Phage &  Antibiotic Resistance 2018 was organized in Florence, Italy in May 17-18, 2018.
 
During two days, more than 100 oral & poster communications were highlighted different axes and topics related to the recent advances and challenges in phage therapy, and to all innovations related to the antibiotic resistance in general.
 
The 5th edition was an excellent platform which gathered more than 200 participants from 33 countries, to share data, ideas, critical comments and opinions alike.
 
After all the high-quality presentations given by internationally renowned phage therapy and antibiotic resistance investigators as well as by young scientists and at the end of the congress, the scientific committee discerned several awards to distinguished speakers:
 
Scientific Achievement Award:
Prof. Richard Novick from New York University, USA was awarded for all his scientific achievements.
 
Prof. Novick gave a strategic presentation about “Reincarnation of a staphylococcal pathogenicity island as an antibacterial drone
For more information, please click here.
 
 
 
Scientific Contribution Award:
Dr Yoon Sung Nam, from Korea Advanced Institute of Science & Technology presented the recent advances and perspectives on Efficient in vivo phage therapy via immunological cloaking. The scientific contribution award was awarded by the scientific committee.
For more information about this award, please click here.
 
 
 
Poster Presentation Award:
The third award was discerned to two young researchers:
 

Thomas Thompson from Queen’s University Belfast, Belfast, Northern Ireland, UK presented a poster about “Halophiles a novel source of antimicrobial natural products
For more information about this award, please click here.
 
Nika Janež from the Centre of Excellence for Biosensors, Instrumentation and Process Control, Ajdovščina, Slovenia presented the “Characteristics of healthy and acne human skin colonization by bacteriophages of propionibacterium acnes and staphylococcus epidermidis and their hosts”.
For more information about this award, please click here.
 
The Abstracts book of Phage Therapy & Antibiotic Resistance 2018 is including all abstracts which were presented with oral and poster communication during the congress.
 
If you didn’t attend the conference, you can order the abstracts book by clicking here.
 
To access the final agenda of Phage Therapy & Antibiotic Resistance 2018, please click here.
 
To access the pictures of Phage Therapy & Antibiotic Resistance 2018, please click here.
 
The scientific committee took on consideration the conclusion of this congress to underline and target the new strategies for the next edition which will be held in 2019. All the practical information will be added soon on the website.
 
Pr Domenico Frezza,  University of Roma Tor Vergata
Local Organizer of Targeting Phage & Antibiotic Resistance

The poster contribution awards were delivered to two young researchers

During Phage Therapy & Antibiotic Resistance Congress 2018, Dr Thomas Thompson from Queen’s University Belfast, Belfast, Northern Ireland, United Kingdom presented a poster about “Halophiles a novel source of antimicrobial natural products”.
 
The aim of this study was “to establish the potential of extremely halophilic microorganisms from Kilroot Salt Mine, Northern Ireland, as a novel source of natural product chemistry with the objective to eventually isolate and structurally elucidate original anti-infective compounds from this unique microbiome. […]”
Dr Thompson demonstrated that “Bio-assay guided fractionation of crude extracts is on-going. Halophiles remain a promising reservoir possessing broad antimicrobial activity, and there is no doubt that exploitation of extreme environments have an important role to play in AMR.”.
 

From her side, Dr Nika Janež from the Centre of Excellence for Biosensors, Instrumentation and Process Control, Ajdovščina, Slovenia presented the “Characteristics of healthy and acne human skin colonization by bacteriophages of propionibacterium acnes and staphylococcus epidermidis and their hosts”.
 
According to Dr Janež:Propionibacterium spp. and Staphylococcus spp. were identified as the predominant and stable inhabitants of healthy human skin. They are considered to be commensal microorganisms though they are associated with development of acne and clinically relevant infections. We aim to determine Propionibacterium acnes and Staphylococcus epidermidis co-colonization characteristics of human skin potentially playing a role in health or disease of the human skin. […] Our small scale study results suggest that P. acnes, S. epidermidis and their bacteriophages are able to co-inhabit healthy human skin, but on acne skin this balance seems to be altered. The bacteriophages were examined more in detail to evaluate their possible ecological and therapeutic potential.”
 
 
The scientific committee

Efficient in vivo phage therapy via immunological cloaking awarded for the best short oral presentation

Dr Yoon Sung Nam from the Korea Advanced Institute of Science and Technology at Daejeon, Republic of Korea was awarded for his short oral presentation about “Efficient in vivo phage therapy via immunological cloaking” during Phage Therapy & Antibiotic Resistance Congress 2018.
 
The aim of Dr Nam’s study was to “immunologically cloaked T7 phage to reduce phagocytosis through genetic expression of CD47-derived self-peptide.  […]”.
In their study, Dr Nam and his team “demonstrated that the in vivo anti-bacterial activity of lytic T7 phage can be dramatically increased by prolonged blood circulation through immunological cloaking with the self-peptide.”
 
The scientific committee

Prof. Richard Novick was awarded for his scientific contribution

During the 5th World Congress on Targeting Infectious Diseases: Targeting Phage &  Antibiotic Resistance 2018 organized in Florence, Italy in May 17-18, 2018, the Scientific Committee awarded Prof. Richard Novick from the School of Medicine of New York University, USA for all his scientific achievements in the field of phage therapy.

Prof. Richard Novick gave a strategic presentation about “Reincarnation of a staphylococcal pathogenicity island as an antibacterial drone”.

 

According to Prof. Novick:

“Staphylococcus aureus, long considered a dangerous, antibiotic resistant pathogen, has recently become more virulent, more contagious and more resistant, especially to B-lactams (MRSA) and glycopeptides (VRSA). Today, it causes a wide variety of life-threatening infections, many of which cannot be treated effectively with conventional antibiotics. Consequently, there is an urgent need for new ways to treat these infections, which annually cause some 18,000 deaths in the US.

We have developed a novel non-antibiotic method for treating staphylococcal infections. This method is based on the naturally-occurring, highly mobile staphylococcal pathogenicity islands (SaPIs). The SaPIs are ~15 kb genetic elements that are stably inserted in the staph chromosome but can be induced by “helper” phages to excise and replicate.

[…] Our plans for the future include two major initiatives: Adding new antibacterial modules to the basic system, and expanding the system to other bacterial pathogens.”

Testimonial from Prof. Novick:

“Although I have devoted much of my career to the study of mobile genetic elements in bacteria and have been deeply concerned for many years about the problems of antibiotic resistance, this was my first visit to the world of phage therapy.  And it was a wonderful visit – not only did I learn a tremendous amount in a field that I knew only peripherally, but also, I found the scientific talks highly informative and very well presented. […] I anticipate the development of collaborations with several of the scientists that I met at the Congress.”

On behalf of the scientific committee
www.tid-site.com

Last practical Information for Phage Therapy Congress Attendees

In few days (May 17-18), you will attend Targeting Phage & Antibiotic Resistance Congress 2018 which will be held at Santa Apollonia Auditorium, in Florence, Italy.

Final agenda
Please click here to access the final agenda.

We remind you that the registration will start at 8:00 on May 17.

Phage Therapy Speed Collaboration
We remind you that you can take part to the Phage Therapy Speed Collaboration which will be organized on May 17 between 17:15 to 18:00.

This session is dedicated to all attendees, academics, start-ups and industrials who are looking for collaboration: each attendee can present his project during one or two minutes to other attendees. If you would like to take part to the Phage Therapy Speed Collaboration, please contact us.

Phage Therapy dinner
The dinner, gathering some attendees and speakers, is organized on May 17 at Hotel Brunelleschi.

Hotel Brunelleschi
Piazza Santa Elisabetta, 3 – 50122 Florence

You can register online here, or on site on May 17.

Poster session
The poster session will be organized during the coffee breaks and lunch breaks of both days.

Certificate of attendance
The certificate of attendance will be sent to all attendees by email after the congress.

Contact
In case of emergency, please contact Prof. Frezza:
frezza@uniroma2.it
tel: 0039 06 7259 4243 or 0039 335 195 6017.

You can also contact us to contact@tid-site.com.

Join Targeting Phage Therapy Dinner

A dinner, gathering some attendees and speakers, is organized on May 17 at Hotel Brunelleschi.

Address of  Restaurant:
Stemma Restaurant
(first floor)
Hotel Brunelleschi

Piazza Santa Elisabetta, 3 – 50122

You can participate to this dinner by booking here.

 


FLORENCE HOTEL BRUNELLESCHI MAP

The Hotel Brunelleschi is located right in the heart of the pedestrian area within the historical center of Florence, just steps away from the Cathedral and the Signoria Square, and overlooking the Via Calzaiuoli. Check out the exact city center location and details of our elegant hotel with the new Google maps locator tool.

Culture-independent discovery of the malacidins as calcium-dependent antibiotics with activity against multidrug-resistant Gram-positive pathogens

Despite the wide availability of antibiotics, infectious diseases remain a leading cause of death worldwide1. In the absence of new therapies, mortality rates due to untreatable infections are predicted to rise more than tenfold by 2050. Natural products (NPs) made by cultured bacteria have been a major source of clinically useful antibiotics. In spite of decades of productivity, the use of bacteria in the search for new antibiotics was largely abandoned due to high rediscovery rates2,3. As only a fraction of bacterial diversity is regularly cultivated in the laboratory and just a fraction of the chemistries encoded by cultured bacteria are detected in fermentation experiments, most bacterial NPs remain hidden in the global microbiome. In an effort to access these hidden NPs, we have developed a culture-independent NP discovery platform that involves sequencing, bioinformatic analysis and heterologous expression of biosynthetic gene clusters captured on DNA extracted from environmental samples. Here, we describe the application of this platform to the discovery of the malacidins, a distinctive class of antibiotics that are commonly encoded in soil microbiomes but have never been reported in culture-based NP discovery efforts. The malacidins are active against multidrug-resistant pathogens, sterilize methicillin-resistant Staphylococcus aureus skin infections in an animal wound model and did not select for resistance under our laboratory conditions.

News source: https://www.nature.com

More than 200 international attendees are already registered for Phage Therapy & Antibiotic Resistance 2018

The 5th World Congress on Targeting Infectious Diseases – Phage Therapy & Antibiotic Resistance will gather more than 200 international attendees coming from industries, start-up and universities working on all infectious diseases related fields.
 
The audience of Phage Therapy 2018 will be composed by attendees coming from all around the world. Among the participants:
 
Queen’s University Belfast
Université Libre de Bruxelles
Eliava Institute of Bacteriophages, Microbiology and Virology
SNIPR biome
Kyorin University
University of Primorska, Faculty of Health Sciences
Universidad Nacional Autonoma de Mexico
University of Lausanne
AmpliPhi
Istituto Zooprofilattico Sperimentale dell’Abruzzo e del Molise “G. Caporale”
EnBiotix
Max Delbrueck Center for Molecular Medicine
Charite University Medicine / Deutsches Rheuma-Forschungszentrum Berlin
G.N. Gabrichevsky Moscow Research Institute for Epidemiology and Microbiology
University of Verona
Lund University
Comsats institute of information technology, Islamabad Pakistan
Polytechnic University of Marche
Institut de Recherche Biomédicale des Armées
G. Eliava Institute of Bacteriophages, Microbiology and Virology
Institut de Recherche Biomédicale des Armées
Jichi Medical University
Central University of Rajasthan
Institute of Microbiology, Norwegian Armed Forces Joint Medical Services
Astellas Pharma Inc
The University of Chicago
Rakuno Gakuen Univ.
university of Naples Federico II
EA Pharma Co.,Ltd.
Rakuno Gakuen University
Clemson University
York University
ITESM – ITE430714KI0
Loughborough University
VIVEXIA
University of Bath
Clean Cells
Biophage Pharma SA
APC Microbiome Ireland, University College Cork
Yale University
The University of Adelaide
Cellabs Pty Ltd
Gothenburg University
University of Gothenburg
Dopharma Research
University of Alabama
Jichi Medical University
Sree Balaji Medical College and Hospital, BIHER-Bharath University
Fudan University
LabMicta
PTC Phage Technology Center GmbH
 

Loughborough University
University of California
Korea Advanced Institute of Science and Technology
University of Lausanne
UCLA
Beiersdorf AG
University of Warwick
IIBR

Sandia National Laboratories
Masaryk University
Institut Cochin
University of Roma Tor Vergata
Fudan University
University of Brighton
University of Florence
National Infections Service
Public Health England
Tufts University
Università degli Studi di Milano
University Zürich
Snipr Biome
Military Institute of Hygiene and Epidemiology
IPLA-CSIC
Hacettepe University
University of Bielefeld
Faculté de Médecine Sorbonne Université
Charles University
Karolinska Institutet
University of Padova
Department of ophthalmology, Kochi Medical School
University of Vienna
BIRD-C
Centre of Excellence for Biosensors, Instrumentation and Process Control
Hankuk University of Foreign Studies
N. Lopatkin Institute of Urology and Interventional radiology
The Queen’s University of Belfast
University of Copenhagen
University of applied sciences of Southern Switzerland
SUPSI – Laboratorio Microbiologia Applicata
Masaryk University
Yale University
Institute of Theoretical and Experimental Biophysics
Russian Academy of Sciences
Phico Therapeutics Limited
University of Wisconsin-Madison
Naval Medical Research Center
University of Ferrara
University of Patras
University of Liege – ULg – Gembloux Agro-Bio Tech
Norwegian University of Life Sciences
University of Lausanne
Intralytix
Emergent Biosolutions
IIBR
Bose Institute

NYU School of Medicine
University of Nottingham
Tel Aviv University
Hebrew University
Erasmus Medical Center
University of Bern
Institute for Infectious Diseases
University of Utah
Uppsala University
University College London
École polytechnique de Montréal Department of Biomedical Engineering
USDA, ARS
Kyorin University Shcool of Medicine
Department of Biotechnology
Norwegian Institute of Public Health
Wageningen University
Univerisity of Florence
Université Libre de Bruxelles
Queen Astrid Military Hospital, Burn Wound Centre
Latrobe University
Universidade de Santiago de Compostela
National Laboratory for Health, Environment and Food Maribor SI19651295
Cell Biology and Immunology Group
RWTH Aachen University
Universidade Federal de Minas Gerais
Medical University of Gdansk
Kochi Medical School
UPMC
Institute of Biochemistry and Biophisics of the Polish Academy of Sciences
Vrije Universiteit Brussel
University of Warsaw
University of Bern
Masaryk University
Azti Tecnalia
CEB – University of Minho
University of Siena
Charité – Universitätsmedizin Berlin
University of Wroclaw
INSERM
Kyorin University
College of Medicine
Alnahrain University
University of Freiburg
Guild BioSciences
JSC “SIC”Microgen”
Vésale Pharma
Beiersdorf AG
AiCuris
JAFRAL
BiomX Ltd.
Phico Therapeutics Ltd
MB Pharma
Animal & Plant Health Agency
Davolterra
MaaT Pharma
and many more…

It is a non-exhaustive list of attendees, and we remind you that you can join all these leaders and save if you register before April 17, midnight by clicking here.
 
For more information: www.tid-site.com